Bionano Genomics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders held by Bionano Genomics, Inc. on June 10, 2021. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in San Diego, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
As of the record date (April 12, 2021), 278,794,489 shares of common stock were outstanding. Approximately 50.5% of outstanding shares (140,681,865 shares) were present at the meeting in person or by proxy. Two proposals were voted upon:
- Proposal 1: Election of Directors
- Christopher Twomey: Elected with 59,405,915 votes for, 6,288,064 votes withheld, and 74,987,886 broker non-votes.
- Yvonne Linney, Ph.D.: Elected with 60,541,510 votes for, 5,152,469 votes withheld, and 74,987,886 broker non-votes.
- Both directors were elected to serve until the 2024 Annual Meeting.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the selection of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Voting Results: 135,470,333 votes for, 879,849 votes against, and 4,331,683 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the new Class III Directors' tenure ending at the 2024 Annual Meeting.
- Verification of BDO USA, LLP's engagement for the fiscal year ending December 31, 2021.
- Analysis of the significant number of broker non-votes (74,987,886) regarding the director elections.
- Review of the high abstention rate (4,331,683) on the auditor ratification proposal.